# Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

> **NCT04508816** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 45 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** cetuximab (CTX) or nimotuzumab (NTZ)

## Key facts

- **NCT ID:** NCT04508816
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508816, "Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04508816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*